Period:
Draw Mode:
| Volume | 401,638 |
|
|||||
| News | - | ||||||
| Day High | 6.74 | Low High |
|||||
| Day Low | 6.53 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| CureVac NV | CVAC | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.25 | 3.88% | 6.69 | 19:58:25 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 6.53 | 6.53 | 6.74 | 6.69 | 6.44 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 3,417 | 401,638 | $ 6.68 | $ 2,684,560 | - | 5.63 - 20.20 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:03:49 | 10 | $ 6.60 | USD |
CureVac NV Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 1.49B | 221.98M | 106.93M | $ 117.14M | $ -101.94M | -2.51 | -14.70 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | - | - |
CureVac NV News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CVAC Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 6.95 | 7.01 | 6.33 | 6.61 | 504,007 | -0.26 | -3.74% |
| 1 Month | 8.60 | 8.74 | 6.33 | 7.31 | 597,802 | -1.91 | -22.21% |
| 3 Months | 6.31 | 12.79 | 6.20 | 9.65 | 1,290,887 | 0.38 | 6.02% |
| 6 Months | 7.83 | 12.79 | 5.63 | 9.07 | 820,377 | -1.14 | -14.56% |
| 1 Year | 18.86 | 20.20 | 5.63 | 11.35 | 675,841 | -12.17 | -64.53% |
| 3 Years | 84.99 | 133.00 | 5.63 | 50.62 | 814,198 | -78.30 | -92.13% |
| 5 Years | 84.99 | 133.00 | 5.63 | 50.62 | 814,198 | -78.30 | -92.13% |
CureVac NV Description
| CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases. |